# US 2003/0073682 A1 · Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073682 A1
- Document ID: US20030073682A1
- Status: Published application
- Kind: A1
- Application number: 10/115,231
- Filed: 2002-04-03
- Published: 2003-04-17
- Earliest claimed: 1998-05-14
- Inventors: Matthew E. Voss; Carl P. Decicco; Ruth R. Wexler
- Web page: https://patentgrep.com/patent/US20030073682A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 279/12: not condensed with other rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application describes novel substituted aryl hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-1 additional heteroatoms selected N, O, and S, which are useful as metalloprotease inhibitors.

## Claims

### Claim 1

A compound of formula I:
81
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
ring A is a 5-8 membered heterocyclic ring containing 0-1 additional heteroatoms selected from the group: O, NH, S, SO, and SO2, and substituted with 0-3 Ra;
Ra, at each occurrence, is independently selected from the group: ═O, CH3, CH2CH3, CF3, Cl, F, OH, OCH3, and OCF3;
Rb, at each occurrence, is independently F or CH3;
X is selected from the group: CH2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)NH, and S(O)2NH;
Y is selected from the group: (CH2)n, OCH2, CH2O, OCH(CH3), CH(CH3)O, OC(CH3)2, C(CH3)2O, OCF2, CF2O, S(O)pCH2, CH2S(O)p, NH, NHCH2, and CH2NH;
Z is CH or N;
R1 is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R2 is selected from the group: F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R3 is selected from the group: F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
provided that when Z is N, R2 and R3 are other than F, Br, or I;
R4 is H;
alternatively, R3 and R4 are taken together with the carbon atoms to which they are attached to form a 5-6 membered aromatic ring containing 0-2 heteroatoms selected from the group: O, S, NH, and N and substituted with 0-2 Rc;
Rc is selected from the group: H, F, Cl, Br, I, NO2, CH3,
CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
when R3 and R4 are taken together, then R2 is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
n is selected from the group: 1, 2, and 3; and,
p is selected from the group: 0, 1, and 2.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein the compound is of formula Ia or Ib:
82
wherein, X is selected from the group: CH2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)NH, and S(O)2NH;
Y is selected from the group: CH2, (CH2)2, OCH2, CH2O, NH, NHCH2, and CH2NH;
Z is CH or N;
R1 is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R2 is selected from the group: F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R3 is selected from the group: F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R4 is H;
alternatively, R3 and R4 are taken together with the aromatic ring to which they are attached to form an aromatic ring selected from a-aa:
83
Rc is selected from the group: H, F, Cl, Br, I, NO2, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3; and,
R2a is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein the compound is selected from:
(S)-4-[[4-[(3,5-dimethylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(3,5-
ditrifluoromethylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(3,5-dibromophenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(3,5-diethoxyphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(3,5-dichlorophenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(2,6-dimethoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(2,6-diethoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(2,6-ditrifluoromethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-4-[[4-[(2,6-dichlorol-4-pyridinyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(2-chloro-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(2-methoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(2-ethoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(2-trifluoromethyl-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
1-[[4-[(3,5-dimethylphenyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(3,5-ditrifluoromethylphenyl)methoxylphenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(3,5-dibromophenyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(3,5-diethoxyphenyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(3,5-dichlorophenyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(2,6-dimethoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(2,6-diethoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[(2,6-ditrifluoromethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-[ (2,6-dichloro-4-pyridinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[[4-(2-chloro-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[[4-(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[[4-(2-methoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[4-(2-ethoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[[4-(2-trifluoromethyl-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(3-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(3-chloro-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
(S)-N-hydroxy-2,2-dimethyl-4-[[[4-(3-methoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]-3-thiomorpholinecarboxamide;
1-[[[4-(3-chloro-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
1-[[[4-(3-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide; and,
1-[[[4-(3-methoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]-D-proline-N-hydroxyamide;
or a pharmaceutically acceptable salt form thereof.

### Claim 4

A compound of formula II:
84
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
ring A is a 5-8 membered heterocyclic ring containing 0-1 additional heteroatoms selected from the group: O, NH, S, SO, and SO2, and substituted with 0-3 Ra;
Ra, at each occurrence, is independently selected from the group: ═O, CH3, CH2CH3, CF3, Cl, F, OH, OCH3, and OCF3;
Rb, at each occurrence, is independently F or CH3;
X is selected from the group: CH2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)NH, and S(O)2NH;
Y′ is S or O;
Z is CH or N;
R1 is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R2 is selected from the group: F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R3 is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
provided that when Z is N, R2 and R3 are other than F, Br, or
R4 is H;
alternatively, R3 and R4 are taken together with the carbon atoms to which they are attached to form a 5-6 membered aromatic ring containing 0-2 heteroatoms selected from the group: O, S, NH, and N and substituted with 0-1 Rc;
Rc is selected from the group: H, F, Cl, Br, I, NO2, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
when R3 and R4 are taken together, then R2 is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
n is selected from 1, 2, and 3; and,
p is selected from 0, 1, and 2.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein the compound is of formula IIa, IIb, IIc or IId:
85
wherein, X is selected from the group: CH2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)NH, and S(O)2NH;
Z is CH or N;
R1 is H or F;
R2 is selected from the group: F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R3 is selected from the group: F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
R4 is H;
alternatively, R3 and R4 are taken together with the aromatic ring to which they are attached to form an aromatic ring selected from a-aa:
86
Rc is selected from the group: H, F, Cl, Br, I, NO2, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3; and,
R2a is selected from the group: H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3.

### Claim 6 (depends on 1)

A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

### Claim 7 (depends on 4)

A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

### Claim 8 (depends on 1)

A method for treating or preventing an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

### Claim 9 (depends on 4)

A method for treating or preventing an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

### Claim 10 (depends on 1)

A method of treating a condition or disease mediated by MMPs, TNF, aggrecanase, or a combination thereof in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

### Claim 11 (depends on 4)

A method of treating a condition or disease mediated by MMPs, TNF, aggrecanase, or a combination thereof in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

### Claim 12 (depends on 1)

A method of reducing levels of TNF in patients without inhibiting MMPs, comprising: MMP-1, MMP-2, and MMP-9, and reduce the potential of side effects mediated by these enzymes comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

### Claim 13 (depends on 4)

A method of reducing levels of TNF in patients without inhibiting MMPs, comprising: MMP-1, MMP-2, and MMP-9, and reduce the potential of side effects mediated by these enzymes comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

### Claim 14 (depends on 1)

A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, multiple sclerosis, neurodegenerative diseases, psoriasis, autoimmune disease, Crohn's disease, inflammatory bowel disease, or HIV infection in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

### Claim 15 (depends on 4)

A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, multiple sclerosis, neurodegenerative diseases, psoriasis, autoimmune disease, Crohn's disease, inflammatory bowel disease, or HIV infection in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

### Claim 16 (depends on 1)

A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, solid tumor growth and tumor invasion by secondary metastases, or neovascular glaucoma, in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

### Claim 17 (depends on 4)

A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, solid tumor growth and tumor invasion by secondary metastases, or neovascular glaucoma, in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.
